Redeye reiterates its positive stance and SEK 50 Base Case on Genovis. At a digital investor meeting yesterday (video with highlights available on our home page), management said real improvements in Asia and early signs of improved customer activity in Europe and the US were encouraging. We still advise investors to use potential weakness to build long-term positions, while cautioning that the current year still is likely to be a ’transition year’ due to the corona crisis. Genovis remains on Redeyes Conviction Buy List.